381 related articles for article (PubMed ID: 33348922)
1. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
2. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
Diaz AK; Baker SJ
Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
[TBL] [Abstract][Full Text] [Related]
3. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
4. Pediatric hemispheric high-grade glioma: targeting the future.
Coleman C; Stoller S; Grotzer M; Stucklin AG; Nazarian J; Mueller S
Cancer Metastasis Rev; 2020 Mar; 39(1):245-260. PubMed ID: 31989507
[TBL] [Abstract][Full Text] [Related]
5. High-throughput microRNA profiling of pediatric high-grade gliomas.
Miele E; Buttarelli FR; Arcella A; Begalli F; Garg N; Silvano M; Po A; Baldi C; Carissimo G; Antonelli M; Spinelli GP; Capalbo C; Donofrio V; Morra I; Nozza P; Gulino A; Giangaspero F; Ferretti E
Neuro Oncol; 2014 Jan; 16(2):228-40. PubMed ID: 24305714
[TBL] [Abstract][Full Text] [Related]
6. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract][Full Text] [Related]
7. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
9. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
10. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).
Bailey CP; Figueroa M; Mohiuddin S; Zaky W; Chandra J
Bioengineering (Basel); 2018 Oct; 5(4):. PubMed ID: 30340362
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
Juratli TA; Qin N; Cahill DP; Filbin MG
Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
[TBL] [Abstract][Full Text] [Related]
13. Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS; Mellinghoff IK
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003625
[TBL] [Abstract][Full Text] [Related]
14. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
15. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
[TBL] [Abstract][Full Text] [Related]
16. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers and targeted therapy in pediatric low-grade glioma.
de Blank P; Fouladi M; Huse JT
J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
[TBL] [Abstract][Full Text] [Related]
18. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Rosenberg T; Yeo KK; Mauguen A; Alexandrescu S; Prabhu SP; Tsai JW; Malinowski S; Joshirao M; Parikh K; Farouk Sait S; Rosenblum MK; Benhamida JK; Michaiel G; Tran HN; Dahiya S; Kachurak K; Friedman GK; Krystal JI; Huang MA; Margol AS; Wright KD; Aguilera D; MacDonald TJ; Chi SN; Karajannis MA
Neuro Oncol; 2022 Nov; 24(11):1964-1975. PubMed ID: 35397478
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
Sturm D; Pfister SM; Jones DTW
J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698
[TBL] [Abstract][Full Text] [Related]
20. Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S; Tabori U; Hawkins C
Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
